Chronic Obstructive Pulmonary Disease. Other chronic obstructive pulmonary disease
Conditions
Interventions
Intervention 1: Vitamin D treatment group will take a pill with a dose of 50,000 IU for 2 months and then will take a pill monthly for 4 months. Intervention 2: Placebo treatment group will take
Treatment - Drugs
Vitamin D treatment group will take a pill with a dose of 50,000 IU for 2 months and then will take a pill monthly for 4 months.
Placebo treatment group will take a placebo pill for 2 months and then a vitamin D placebo pill monthly for 4 months.
Sponsors
Vice chancellor of research ,Guilan University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The inclusion of study criteria are as following : the proof of COPD diagnosis according to clinical conditions and its approval with spirometry based on GOLD ; low serum levels of 25-hydroxyvitamin D (10-30) as insufficiency. The study exclusion criteria : hypercalcemia ; ca more than10.3 ; sarcoidosis (according to diagnosis and clinical examination of pulmonary subspecialty ; cancer (asking the patient) ; osteoprosis that has recently been diagnosed (asking the patient) ; long term use of azithromycin (asking the patient) ; serum 25-hydroxy vitamin D levels less than 10 as deficiency ; thyroid and parathyroid diseases.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The rate of change in COPD stage according to GOLD stages. Timepoint: The time of study inclusion and one month later and 6 months later. Method of measurement: Spirometry.;Evaluation of quality of life of patients. Timepoint: The time of study inclusion and one month later and 6 months later. Method of measurement: CAT Questionnair.;Serum levels of 25-hydroxyvitamin D. Timepoint: The time of study inclusion and one month later and 6 months later. Method of measurement: Measurement of serum levels of 25-hydroxyvitamin D. | — |
Secondary
| Measure | Time frame |
|---|---|
| Mortality. Timepoint: During study. Method of measurement: Recording in patients’ information forms.;The duration of taking Systemic steroids and antibiotics. Timepoint: During the study. Method of measurement: Recording in patients’ information forms.;Number of exacerbations. Timepoint: duringt study. Method of measurement: recording in patients’ information forms.;The median time of the occurrence of the first exacerbation during the study. Timepoint: during study. Method of measurement: recording in patients’ information forms. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSara Massahnia
Respiratory Research Center of Guilan University Medical Sciences
Outcome results
None listed